Lithium for Parkinson's: an Extension Trial

Part of paid clinical trials in Williamsville, New York.

Sponsor
State University of New York at Buffalo
Study ID
NCT06592014
Phase
PHASE1/PHASE2
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
45 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Lithium aspartate — DIETARY_SUPPLEMENT
    Lithium aspartate with dosage adjusted to serum lithium level 0.25-0.50mmol/L

Study Details

This study will examine the effects of 24 weeks of lithium therapy achieving serum lithium levels of 0.25-0.50mmol/L on MRI and blood-based biomarkers in Parkinson's disease patients who have completed one of our current 24-week lithium clinical trials.

Key Dates

Start date
Aug 9, 2024
Status verified
Nov 2025
Primary completion
Jun 1, 2026
Completion
Nov 1, 2026

Study Design

Enrollment
35 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Lithium aspartate
    Lithium aspartate with dosage adjusted to achieve a serum lithium level of 0.25-0.50mmol/L

Primary Outcome Measure

Free Water [ Time Frame: 24 Weeks. ]

Locations (1)

FacilityCityStateZIPSite coordinators
UBMD NeurologyWilliamsvilleNew York14221-

Find similar trials in Williamsville, NY

By condition
Parkinson's disease
By specialty
NeurologyBrain disorders
By research site
UBMD Neurology· Williamsville, NY

Related Studies